-
Listing
-
Trading
Where European Government Bonds meet the futureFixed Income derivativesLer maisTrade Mini Bond Futures on main European Government Bonds
-
Clearing
Step into Europe’s next phase of Repo ClearingRepo ClearingLer maisEuronext is expanding its repo clearing services to boost market access, liquidity provision and collateral optimisation across Europe.
-
CSD
European CSD modelBuilding the CSD of Choice in EuropeLer maisEuronext Securities is shaping the future of European capital markets by enhancing integration, connectivity, and innovation.
-
Technology
Euronext Technology SolutionsHigh-Frequency Trading Solution (HFTS)Ler maisThe new generation of high-frequency risk trading platforms, offering the highest performance with ultra-low latency and minimal jitter, all at a low total cost of ownership.
-
Data
-
Indices
Access the white paperInvesting in the future of Europe with innovative indicesLer maisThe first edition of the Euronext Index Outlook series with a particular focus on the European Strategic Autonomy Index.
-
About Euronext
Euronext strategic planInnovate for Growth 2027Ler maisShaping capital markets for future generations
Kiadis Pharma
04/06/2018
Kiadis Pharma sounds the gong in Amsterdam
Kiadis Pharma (ticker symbol: KDS), received this year’s tech 40 label from Euronext. Companies with the Tech 40 label are young technology companies listed on Euronext markets and operating in life sciences, eco-industries or TMT. An independent group of European experts selected the first 40 on the basis of their business, financial and stock market performance.
Kiadis Pharma is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders.
For more information: www.kiadis.com